Art

J-GLOBAL ID：202002256376248994   Reference number：20A0444529

Antitumor activity of the PD-1/PD-L1 binding inhibitor BMS-202 in the humanized MHC-double knockout NOG mouse

ヒト化MHCダブルノックアウトNOGマウスにおけるPD-1/PD-L1結合阻害剤BMS-202の抗腫瘍活性

Author (12)： ASHIZAWA Tadashi (Immunotherapy Division, Shizuoka Cancer Center Research Institute) ,  IIZUKA Akira (Immunotherapy Division, Shizuoka Cancer Center Research Institute) ,  TANAKA Emiko (Immunotherapy Division, Shizuoka Cancer Center Research Institute) ,  KONDOU Ryota (Immunotherapy Division, Shizuoka Cancer Center Research Institute) ,  MIYATA Haruo (Immunotherapy Division, Shizuoka Cancer Center Research Institute) ,  MAEDA Chie (Immunotherapy Division, Shizuoka Cancer Center Research Institute) ,  SUGINO Takashi (Division of Pathology, Shizuoka Cancer Center Hospital) ,  YAMAGUCHI Ken (Office of the president, Shizuoka Cancer Center Hospital) ,  ANDO Takayuki (Shizuoka Institute of the Environment and Hygiene) ,  ISHIKAWA Yoshinobu (School of Pharmaceutical Sciences, University of Shizuoka) ,  ITO Mamoru (Central Institute for Experimental Animals) ,  AKIYAMA Yasuto (Immunotherapy Division, Shizuoka Cancer Center Research Institute)
Material： Biomedical Research (Web)
Volume： 40  Issue： 6  Page： 243-250(J-STAGE)  Publication year： 2019 
JST Material Number： U1102A  ISSN： 1880-313X  Document type： Article
Article type： 原著論文  Country of issue： Japan (JPN)  Language： ENGLISH (EN)

Thesaurus term： Mus musculus ,...
Semi thesaurus term： *PD-1 ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=20A0444529&from=J-GLOBAL&jstjournalNo=U1102A") }}

JST classification (2)： Experimental treatment for tumors  (GE02040Y) ,  Basic research of antitumor(=antineoplastic)drugs  (GW16010A)

Substance index (1)： BMS-202

Reference (33)：

• 1 Abdel-Magid AF (2015) Inhibitors of the PD-1/PD-L1 pathway can mobilize the immune system: an innovative potential therapy for cancer and chronic infections. ACS Med Chem Lett 6, 489-490.
• 2 Akiyama Y, Nonomura C, Kondou R, Miyata H, Ashizawa T, Maeda C, Mitsuya K, Hayashi N, Nakasu Y and Yamaguchi K (2016) Immunological effects of the anti-programmed death-1 antibody on human peripheral blood mononuclear cells. Int J Oncol 49, 1099-1107.
• 3 Akiyama Y, Nonomura C, Ashizawa T, Iizuka A, Kondou R, Miyata H, Sugino T, Mitsuya K, Hayashi N, Nakasu Y, et al. (2017) The anti-tumor activity of the STAT3 inhibitor STX0119 occurs via promotion of tumor-infiltrating lymphocyte accumulation in temozolomide-resistant glioblastoma cell line. Immunol Lett 190, 20-25.
• 4 Ashizawa T, Iizuka A, Nonomura C, Kondou R, Maeda C, Miyata H, Sugino T, Mitsuya K, Hayashi N, Nakasu et al. (2017) Antitumor effect of programmed death-1 (PD-1) blockade in humanized the NOG-MHC double knockout mouse. Clin Cancer Res 23, 149-158.
• 5 Basu S, Yang J, Xu B, Magiera-Mularz K, Skalniak L, Musielak B, Kholodovych V, Holak TA and Hu L (2019) Design, synthesis, evaluation, and structural studies of C2-symmetric small molecule inhibitors of programmed cell death-1/programmed death-ligand 1 protein-protein interaction. J Med Chem 62, 7250-7263.

Terms in the title (8)： MHC ,  ノックアウト ,  NOGマウス ,  PD-1 ,  PD-L1 ,  阻害剤 ,  BMS ,  抗腫瘍活性